A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

作者信息Eugenio Morelli, Mariateresa Fulciniti, Mehmet K Samur, Caroline F Ribeiro, Leon Wert-Lamas, Jon E Henninger, Annamaria Gullà, Anil Aktas-Samur, Katia Todoerti, Srikanth Talluri, Woojun D Park, Cinzia Federico, Francesca Scionti, Nicola Amodio, Giada Bianchi, Megan Johnstone, Na Liu, Doriana Gramegna, Domenico Maisano, Nicola A Russo, Charles Lin, Yu-Tzu Tai, Antonino Neri, Dharminder Chauhan, Teru Hideshima, Masood A Shammas, Pierfrancesco Tassone, Sergei Gryaznov, Richard A Young, Kenneth C Anderson, Carl D Novina, Massimo Loda, Nikhil C Munshi
PMID36126301
期刊Blood
发布时间2023-01-26
DOI10.1182/blood.2022016892

摘要

Long noncoding RNAs (lncRNAs) can drive tumorigenesis and are susceptible to therapeutic intervention. Here, we used a large-scale CRISPR interference viability screen to interrogate cell-growth dependency to lncRNA genes in multiple myeloma (MM) and identified a prominent role for the miR-17-92 cluster host gene (MIR17HG). We show that an MIR17HG-derived lncRNA, named lnc-17-92, is the main mediator of cell-growth dependency acting in a microRNA- and DROSHA-independent manner. Lnc-17-92 provides a chromatin scaffold for the functional interaction between c-MYC and WDR82, thus promoting the expression of ACACA, which encodes the rate-limiting enzyme of de novo lipogenesis acetyl-coA carboxylase 1. Targeting MIR17HG pre-RNA with clinically applicable antisense molecules disrupts the transcriptional and functional activities of lnc-17-92, causing potent antitumor effects both in vitro and in vivo in 3 preclinical animal models, including a clinically relevant patient-derived xenograft NSG mouse model. This study establishes a novel oncogenic function of MIR17HG and provides potent inhibitors for translation to clinical trials.

实验方法

产品清单